Biological Evaluation of 5′-(N-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biological Evaluation of 5′-(N-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors
Authors
Keywords
-
Journal
ACS Medicinal Chemistry Letters
Volume 12, Issue 3, Pages 373-379
Publisher
American Chemical Society (ACS)
Online
2021-03-01
DOI
10.1021/acsmedchemlett.0c00509
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overexpression of molecule GRP94 favors tumor progression in lung adenocarcinoma by interaction with regulatory T cells
- (2020) Xiao‐Feng Duan et al. Thoracic Cancer
- Multiple adenosine receptor subtypes stimulate wound healing in human EA.hy926 endothelial cells
- (2019) Zeinab Bonyanian et al. Purinergic Signalling
- NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90
- (2019) John D. Huck et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Involvement of adenosine A2B receptor in radiation-induced translocation of epidermal growth factor receptor and DNA damage response leading to radioresistance in human lung cancer cells
- (2019) Kazuki Kitabatake et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Glucose-regulated protein of 94 kDa contributes to the development of an aggressive phenotype in breast cancer cells
- (2018) Pedro Buc Calderon et al. BIOMEDICINE & PHARMACOTHERAPY
- Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding
- (2018) Nanette L. S. Que et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor
- (2018) Anuj Khandelwal et al. Nature Communications
- Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors
- (2017) Hye-Kyung Park et al. JOURNAL OF MEDICINAL CHEMISTRY
- Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
- (2016) Absarul Haque et al. CURRENT PHARMACEUTICAL DESIGN
- Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold
- (2016) Vincent M. Crowley et al. JOURNAL OF MEDICINAL CHEMISTRY
- 5′-N -ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor
- (2016) Shanshan Liu et al. PROTEIN SCIENCE
- Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma
- (2014) Andrew R. Stothert et al. HUMAN MOLECULAR GENETICS
- Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
- (2013) Pallav D Patel et al. Nature Chemical Biology
- Structure, Function and Regulation of the Hsp90 Machinery
- (2013) Johannes Buchner et al. Biomedical Journal
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- The Therapeutic Target Hsp90 and Cancer Hallmarks
- (2012) Yoshihiko Miyata et al. CURRENT PHARMACEUTICAL DESIGN
- Glucose-regulated Protein 94 Triage of Mutant Myocilin through Endoplasmic Reticulum-associated Degradation Subverts a More Efficient Autophagic Clearance Mechanism
- (2012) Amirthaa Suntharalingam et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Molecular Chaperone gp96/GRP94 Interacts with Toll-like Receptors and Integrins via Its C-terminal Hydrophobic Domain
- (2012) Shuang Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started